Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib

NCT04285723 · clinicaltrials.gov ↗

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

PIK3CA-Related Overgrowth Spectrum (PROS)

Interventions

OTHER: alpelisib

Sponsor

Novartis Pharmaceuticals